Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Declines By 51.5%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large drop in short interest in March. As of March 13th, there was short interest totaling 3,741 shares, a drop of 51.5% from the February 26th total of 7,709 shares. Based on an average trading volume of 2,988 shares, the days-to-cover ratio is currently 1.3 days.

enGene Stock Performance

Shares of ENGNW stock traded down $0.27 on Friday, hitting $2.04. 1,157 shares of the stock traded hands, compared to its average volume of 18,370. The company’s fifty day moving average is $3.01 and its 200 day moving average is $2.39. enGene has a 1-year low of $0.51 and a 1-year high of $4.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.